文章基本信息

标题：Sodium-glucose co-transporter 2 inhibitors – a review article
本地全文：下载
作者：Marcin Makuch ; Marcelina Makuch ; Ewa Krzewicka-Romaniuk 等
期刊名称：Journal of Education, Health and Sport
电子版ISSN：2391-8306
出版年度：2019
卷号：9
期号：9
页码：42-49
DOI：10.5281/zenodo.3372353
语种：English
出版社：Kazimierz Wielki University
摘要：Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus. An alternative strategy is to enhance urinary glucose excretion by targeting renal sodium-glucose co-transporters (SGLTs). Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce blood glucose by increasing urinary glucose excretion and present a valuable therapeutic option for the treatment of type 2 diabetes. Presently, clinically available SGLT2 inhibitors include canagliflozin, dapagliflozin and empagliflozin [1, 2].
关键词：Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus. An alternative strategy is to enhance urinary glucose excretion by targeting renal sodium-glucose co-transporters (SGLTs). Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce blood glucose by increasing urinary glucose excretion and present a valuable therapeutic option for the treatment of type 2 diabetes. Presently, clinically available SGLT2 inhibitors include canagliflozin, dapagliflozin and empagliflozin [1, 2].